📊 AXSM Key Takeaways
Investment Thesis
Axsome exhibits strong revenue growth of 65.5% YoY, demonstrating market traction for its pharmaceutical products. However, the company is deeply unprofitable with -28.7% net margins, substantial operating losses of -$166.8M, and negative free cash flow of -$93.9M, indicating the business is not yet self-sustaining. While the $322.9M cash position provides runway, the current burn rate and path to profitability remain concerning for investors.
AXSM Strengths
- Exceptional revenue growth of 65.5% YoY demonstrates strong market demand and successful commercialization
- Solid liquidity position with $322.9M cash and 1.55x current ratio providing financial flexibility
- Improving diluted EPS trend with 38.6% YoY improvement despite continued losses shows cost discipline
AXSM Risks
- Chronic unprofitability with -$183.2M net income and -$93.9M operating cash flow indicating unsustainable business model
- High leverage with 1.33x debt-to-equity ratio and $117.7M long-term debt while company is cash flow negative
- Significant cash burn rate of $93.9M in free cash flow could deplete $322.9M reserves within 3-4 years without profitability
Key Metrics to Watch
- Path to operating profitability and timeline to positive operating cash flow
- Cash runway and burn rate trajectory given current spending levels
- Revenue growth sustainability and gross margin expansion as volumes scale
AXSM Financial Metrics
💡 AI Analyst Insight
Axsome Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
AXSM Profitability Ratios
AXSM vs Healthcare Sector
How Axsome Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
AXSM Balance Sheet & Liquidity
AXSM 5-Year Financial Trend
5-Year Trend Summary: Axsome Therapeutics, Inc.'s revenue has grown significantly by 1,176% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.27 indicates the company is currently unprofitable.
AXSM Growth Metrics (YoY)
AXSM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $104.8M | -$47.2M | $-0.94 |
| Q2 2025 | $87.2M | -$48.0M | $-0.97 |
| Q1 2025 | $75.0M | -$59.4M | $-1.22 |
| Q3 2024 | $57.8M | -$11.2M | $-1.32 |
| Q2 2024 | $46.7M | -$11.2M | $-1.54 |
| Q1 2024 | $75.0M | -$11.2M | $-0.26 |
| Q3 2023 | $16.8M | -$11.2M | $-1.07 |
| Q2 2023 | $8.8M | -$11.2M | $-1.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AXSM Capital Allocation
AXSM SEC Filings
Access official SEC EDGAR filings for Axsome Therapeutics, Inc. (CIK: 0001579428)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AXSM
What is the AI rating for AXSM?
Axsome Therapeutics, Inc. (AXSM) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are AXSM's key strengths?
Exceptional revenue growth of 65.5% YoY demonstrates strong market demand and successful commercialization. Solid liquidity position with $322.9M cash and 1.55x current ratio providing financial flexibility.
What are the risks of investing in AXSM?
Chronic unprofitability with -$183.2M net income and -$93.9M operating cash flow indicating unsustainable business model. High leverage with 1.33x debt-to-equity ratio and $117.7M long-term debt while company is cash flow negative.
What is AXSM's revenue and growth?
Axsome Therapeutics, Inc. reported revenue of $638.5M.
Does AXSM pay dividends?
Axsome Therapeutics, Inc. does not currently pay dividends.
Where can I find AXSM SEC filings?
Official SEC filings for Axsome Therapeutics, Inc. (CIK: 0001579428) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AXSM's EPS?
Axsome Therapeutics, Inc. has a diluted EPS of $-3.68.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.